Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.19
-0.17 (-1.18%)
At close: May 12, 2025, 4:00 PM
14.18
-0.01 (-0.08%)
After-hours: May 12, 2025, 7:48 PM EDT
Takeda Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T JPY with 7.45% growth. Takeda Pharmaceutical had revenue of 1.05T in the quarter ending March 31, 2025, with 0.24% growth.
Revenue (ttm)
4,581.55B JPY
Revenue Growth
+7.45%
P/S Ratio
1.39
Revenue / Employee
92,967,898 JPY
Employees
49,281
Market Cap
42.50B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TAK News
- 1 day ago - Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha
- 3 days ago - Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 4 days ago - Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress - Business Wire
- 7 days ago - BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers - Business Wire
- 12 days ago - Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education - Business Wire
- 4 weeks ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 5 weeks ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha